COSELA™ (Trilaciclib)
- Medicine Name: Cosela
- Generic Name: Trilacicilib
- Dosage Form & Strength: Injection: 300 mg
- Manufactured By: G1 Therapeutics, Inc.
- Administration of Trilacicilib can be responsible for causing injection-site reactions including phlebitis and thrombophlebitis. Assess patients for signs/symptoms of injection-site reactions, phlebitis, and thrombophlebitis, including infusion-site pain and erythema during infusion.
- Administration of Trilacicilib 300 mg injection can cause acute drug hypersensitivity reactions, including facial edema and urticaria. Evaluate patients for signs/symptoms of acute drug hypersensitivity reactions including eye, facial, and tongue edema, pruritus, urticaria, and anaphylactic reactions.
- Serious, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can emerge in patients treated with cyclin-dependent kinases (CDK)4/6 inhibitors, the same drug class as Trilacicilib.
- Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as dyspnea, cough, and hypoxia. For recurrent moderate ILD/pneumonitis, permanently interrupt Trilacicilib. For severe or life-threatening (Grade 4) ILD/pneumonitis, permanently interrupt Trilacicilib.
- Based on its mechanism of action, Cosela 300 mg injection can cause fetal harm if administered to a pregnant woman. Females of reproductive age should use an apt contraception during treatment and for at least three weeks after the final dose.
- Because of the potential for severe adverse reactions in breastfed children, lactating women should not breastfeed while taking treatment with trilacicilib injectable and for at least 3 weeks after the final dose.
What documents are required to import COSELA to India?
COSELA (trilacicilib) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is COSELA available in India?
COSELA (trilacicilib injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Cosela injection in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Pune, Chennai and Bangalore etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
COSELA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of COSELA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Cosela injection price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the COSELA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Cosela®?
Trilacicilib is Generic Name for the trade name drug Cosela®.
What is the Manufacturer Name of Cosela®?
Cosela® is manufactured by G1 Therapeutics, Inc.
Is Cosela® approved by the FDA?
Yes, Cosela® is approved by the FDA. Date of approval: February 12, 2021.
What is Cosela®?
Cosela® is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor myelopreservation therapy for use in patients with SCLC who are receiving chemotherapy.
What is the dosage and form of Cosela® supplied?
Cosela® is supplied for injection: 300 mg of trilaciclib as a lyophilized cake in a single-dose vial for intravenous administration.
What are the most common side effects due to Cosela®?
Most common side effects due to Cosela® include: fatigue, hypokalemia, hypocalcemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.
How much does Cosela® cost in India?
Cosela cost in India is reasonable. In order to procure this small cell lung cancer medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Cosela®?
Store the vials of Cosela at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). The vial stopper is not made with natural rubber latex.
What are the Highlights of prescribing information for Cosela®?
Click Here to download full Cosela prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.